Indication

Homozygous familial hypercholesterolemia

Homozygous familial hypercholesterolemia is a rare, life-threatening genetic metabolic disorder affecting the cardiovascular system, caused by biallelic pathogenic mutations in genes critical to low-density lipoprotein clearance, most commonly the low-density lipoprotein receptor gene. Read more about Homozygous familial hypercholesterolemia

189 drugs 97 manufacturers

Advertisement

Drugs that treat it

Common Homozygous familial hypercholesterolemia therapies.

Showing 37–45 of 189 drugs

ROSUVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
TORRENT PHARMAC

ROSUVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
CAMBER PHARMACE

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
TEVA USA

SIMVASTATIN

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+13
BIOCON PHARMA I

ROSUVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
ASCEND LABORATO

ROSUVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
GEN-SOURCE RX

ROSUVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
BIOCON PHARMA I
Filter & compare in the drug finder →Opens the drug finder with Homozygous familial hypercholesterolemia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Homozygous familial hypercholesterolemia.

Homozygous familial hypercholesterolemia is a rare, life-threatening genetic metabolic disorder affecting the cardiovascular system, caused by biallelic pathogenic mutations in genes critical to low-density lipoprotein clearance, most commonly the low-density lipoprotein receptor gene.

This condition primarily manifests in children and young adults and is pathophysiologically defined by absent or severely blunted low-density lipoprotein receptor function, resulting in profound elevations of circulating low-density lipoprotein cholesterol typically exceeding 400 to 500 mg/dL.

Clinically, affected individuals develop physical signs of lipid deposition—such as cutaneous planar, tendon, or tuberous xanthomas and corneal arcus—alongside accelerated, premature atherosclerotic cardiovascular disease, aortic stenosis, and ischemic cardiac events often presenting before the second or third decade of life.

Personalize your experience

Follow Homozygous familial hypercholesterolemia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it